Timo Minssen

Timo Minssen is Professor of Law at the University of Copenhagen and Founding Director of the Center for Advanced Studies in Bioscience Innovation Law (CeBIL). He holds affiliations as an Inter-CeBIL Research Affiliate at the Petrie-Flom Center (Harvard Law School) and an LML Research Affiliate at the University of Cambridge. His career spans roles such as TUM Global Visiting Professor (Technical University of Munich), Visiting Scholar at Harvard, Oxford, and Cambridge, and PI for the Novo Nordisk Foundation’s Inter-CeBIL research program.

• Education: German Staatsexamen (Göttingen), Swedish LL.M., LL.Lic., and LL.D. (Lund & Uppsala Universities).
• Specializations: Intellectual Property, Competition & Regulatory Law in health/life sciences; focuses on genome editing, AI, big data, and quantum technologies.

His research bridges legal, ethical, and commercial challenges in biomedical innovation, emphasizing sustainable R&D regulation, open innovation, and technology transfer. He has published over 220 articles in journals like Science, Nature Biotechnology, and JAMA, with themes spanning pharmaceutical patent law, bioethics, and AI governance.

• Scientific awards: King Oscar Award (2014), Jorcks Foundation Prize (2017), Awapatent Research Prize (2009).
• Grants: Novo Nordisk Foundation (50 million DKK), EU Horizon, SSHRC, Wallenberg Project.

He advises the WHO, WIPO, and EU Commission on digital health, AMR, and AI policy, and supervises PhD students in areas like CRISPR licensing, antimicrobial resistance, and pharmaceutical regulation. His work appears in media outlets such as The Economist, Politico, and The Lancet Digital Health.